INTRODUCTION
A20, encoded by TNFAIP3 on chromosome 6, is an ubiquitin editing enzyme that plays a central role in the control of NF-kB activation. This enzyme is expressed in most cell types at low basal levels but is rapidly induced upon tumor necrosis factor (TNF) or Toll Like Receptor (TLR) mediated NF-kB activation. Once expressed, A20 acts as a negative feedback regulator of NF-KB activation via its Ovarian Tumor (OTU) and zinc finger domains and is a central regulator of inflammation; A20 knockout mice die during the neonatal period due to severe, uncontrolled inflammation leading to cachexia 1 2 .
Genome wide association studies (GWAS) have demonstrated association between
TNFAIP3 polymorphisms and risk of rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), systemic sclerosis (SSc) and other autoimmune diseases 3, 4 . Many of these studies demonstrated association with an exonic single nucleic polymorphism (SNP), rs2230926, located in exon 3 and leading to replacement of phenylalanine by cysteine at amino acid position 127 (rs2230926 T>G; F127C) 5 .
In addition to its role in autoimmunity, A20 inactivation in tumor cells has been found in a number of lymphomas, particularly the mucosa associated lymphoid tissue (MALT) type of marginal zone lymphoma 4, [6] [7] [8] [9] . In accordance with the well-established role of excessive NFkB activation in the development of lymphoid malignancies 10 , A20/TNFAIP3 is considered a potent tumor suppressor gene in B cell lymphoma.
Several autoimmune diseases, including RA, SLE, and primary Sjögren's syndrome (pSS)
are associated with an increased risk of malignant lymphoma, presumably related to the underlying chronic inflammatory process 11 . pSS is a prototypic autoimmune disorder characterized by lymphocytic infiltration of salivary and lacrimal glands leading to xerostomia and xerophtalmia. Chronic polyclonal B-cell activation is commonly present, which may
For personal use only. on August 31, 2017. by guest www.bloodjournal.org From explain why this autoimmune disease has the strongest association with the development of B-cell lymphoma (relative risks of 15 to 20) . Most lymphomas in pSS are typically localized in the salivary glands, the target organs of pSS, and more generally in the extra-nodal MALT.
Given the relevance of A20 to both autoimmunity and lymphomagenesis, we studied germline and somatic abnormalities of TNFAIP3 among a well-characterized cohort of pSS patients, some of whom had also developed lymphoma. Lymphomas were classified according to the current WHO classification 13 .
Informed consent was obtained from all subjects in accordance with the Declaration of Helsinki, and the study was approved by the local ethics committee.
Germline DNA was extracted from peripheral blood mononuclear cells (PBMC). Lymphoma DNA was extracted from paraffin embedded tumor tissues (supplementary methods).
Genotyping
Three SNPs within the TNFAIP3 gene region that have been associated with SLE among individuals of European ancestry 5 were genotyped from germline DNA. rs2230926 is located in exon 3 and rs13192841 and rs6922466 map to within 250 kb upstream and downstream of the TNFAIP3 region, respectively. Genotyping employed a predesigned TaqMan assay from Applied Biosystems (Foster City, CA, USA; assay no. 26882391-1) using a competitive allele-specific PCR system (KASpar genotyping, http://www.lgcgenomics.com/) as previously described 14 . All subjects were also genotyped for 48 ancestry informative markers (AIMs) selected to be highly informative for continental ancestry 15 (list available upon request) to
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TNFAIP3 exon sequencing
Sequencing of the 8 coding exons (2 to 9) of the TNFAIP3 gene, as well as exon/intron junctions, exon 1 (which is not coding), part of intron 5 and part of the 3' intronic region was performed on germline and lymphoma DNA using the Sanger method (supplementary methods). All SNPs, mutations or losses of heterozygosity (LOH) identified by Sanger sequencing were confirmed by pyrosequencing methods (supplementary methods).
Measurement of TNFAIP3 mRNA level by quantitative Reverse Transcription PCR (q-

RT-PCR)
RNA was extracted from PBMC using the RNeasy Mini kit (Qiagen 
RESULTS
Characteristics of patients
Patients with pSS
574 patients with pSS were studied, including 335 (57%) with anti-SSA antibodies, 176 (30%) with both anti-SSA and anti-SSB antibodies and 307 (52%) with previous or current systemic complications, including skin, muscular, articular, renal or neurological involvement and/or history of lymphoma.
Patients with pSS and lymphoma
A total of 44 patients with pSS and lymphoma were studied, including 25 in the initial genetic association analyses (discovery set) and 19 additional patients available for TNFAIP3 exome sequencing of both germline and somatic DNA. . Individual characteristics of the 44 patients with lymphoma are presented in supplementary Table 1 .
The most frequent histologic type was MALT lymphoma, which occurred in 28/44 (63.6%) patients and were primarily identified in the parotid glands (14/28, 50%), with others localized to the salivary glands (4/28, 14.2%), cavum (3/28, 10.7%), stomach (2/28, 7%), lung (2/28, 7%), skin (1/28, 3.5%), ocular adnexal (1/28, 3.5%) and thymus (1/28, 3.5%). Seven (25 %) patients with MALT lymphoma presented with disseminated disease (stage IV) and 21 (75 %) with localized disease (stage IE). There were 4 patients with nodal marginal zone lymphoma (MZL), 2 with splenic MZL, 1 follicular lymphoma, and 1 lymphocytic lymphoma.
Five patients presented with a high grade diffuse large cell lymphoma (DLCL). One patient each presented with Hodgkin's and T-cell lymphoma (fungoid mycosis). One patient with a history of immunosuppressive treatment with azathioprine and methotrexate had an EBVassociated B cell lymphoproliferative disorder.
The rs2230926 SNP is associated with the development of lymphoma in pSS patients
For the initial genetic association study, a total of 574 independent pSS cases, including 25 with lymphoma, and 451 independent controls were analyzed for the 3 TNFAIP3 SNPs and Figure 1A) .
We did not observe an association at a significance level of p<0.05 between these 3 SNPs and pSS (Table 1A) ; however we had low power (<25%) for the observed effect size (OR=1.26). Similarly, these SNPs were not associated (at p<0.05) with the presence of autoantibodies (anti-SSA, or anti-SSA + anti-SSB) or with the occurrence of systemic involvement (Table 1B ) when compared to controls; for these analyses we had approximately 38-60% power for the observed ORs (OR=1.54 and 1.66 respectively).
However, the rs2230926G variant was significantly associated with the development of lymphoma in pSS patients (OR=3. (Table 1C) .
TNFAIP3 germline abnormalities in pSS patients with lymphoma
Frequency of the rs2230926 polymorphism.
Among the 43 patients with pSS and lymphoma who underwent TNFAIP3 sequencing of germline DNA, the rs2230926G risk variant was present in 11 (26%) (OR=2. (Figure 1 and Table 2A) We also identified a novel 24 bp deletion (CCCGGAGAGGTAACCGCCGCGCCT/-) in exon 1 (termed New 1), which results in suppression of a potential Sp1 binding site within the promoter. This deletion occurred in 4 patients, 2 of whom also had the rs2230926G allele. In another patient with rs2230926G, we identified a novel variant within exon 9 (Arg742Ser), termed New 2. Lastly, we studied the TT>A polymorphic dinucleotide located in the 3' UTR that was recently reported to be associated with risk of SLE and is in strong linkage disequilibrium (LD) with rs2230926G 18 . We observed the TT>A variant in 5 patients, all of whom had the rs2230926G allele, however an additional 6 patients had the rs2230926G without the TT>A variant. Thus, these variants are in complete LD (D'=1) but not perfectly correlated (r 2 < 1.0).
To summarize, 13/43 (30%) pSS patients with lymphoma studied had a potentially functional germline abnormality of A20: 11 with the rs2230926G variant resulting in Phe/Cys at amino acid position 127 (2 with and 2 without the exon 1 24 bp deletion resulting in suppression of a Sp1 binding site); and 2 without rs2230926G but with the exon 1 24 bp deletion ( Figure 1 and Table 1A ).
TNFAIP3 lymphoma abnormalities in pSS patients with lymphoma
Lymphoma samples were obtained from 34/44 patients. High-quality DNA was available for 21 of these patients, all but one of whom had germline DNA available. We focused on these 20 patients with paired germline and lymphoma TNFAIP3 sequence data. Importantly, these 20 patients were comparable to the entire cohort of pSS patients with lymphoma in terms of the main clinical characteristics (Supplementary table S2 (Table 2A) . One patient had an insertion of 2 nucleotides (GG) in exon 3 leading to a stop codon (New 3). Another patient had a guanine to adenine mutation in exon 2 (New 4) leading to a stop codon in position 85 (Figure 1) . We found loss of heterozygosity (LOH) corresponding to hemizygous deletion in 3 patients, one of whom had 3 different LOH suggesting that a large deletion occurred in TNFAIP3 in tumor DNA. Lastly, an additional patient had an extensive lymphoma deletion associated with a germline coding abnormality (rs2230926G) (Patient 2, Table 2B ). Sanger sequences of lymphoma variants not found in germline DNA are presented in Figure 2 . To summarize, 12/20 (60%) patients in whom both germline and lymphoma DNA were available had a potentially functional abnormality of A20, either inherited or acquired. Germline abnormalities comprised an amino acid substitution in the case of the rs2230926G variant and/or the potential suppression of a Sp1 binding site in the case of the 24 bp deletion. Lymphoma abnormalities consisted of 2 mutations leading to a stop codon and 4 deletions leading to a truncated protein.
Abnormalities of A20 according to lymphoma type
Among the 20 patients in whom both germline and lymphoma DNA were available, 65% had MALT lymphoma and among this subgroup, 77% had potentially functional abnormalities of A20 compared to 28.6% of patients with other types of lymphoma (p<0.0001, Table 3 ).
Functional consequences of A20 abnormalities
Measurement of TNFAIP3 mRNA level by quantitative RT-PCR (q RT-PCR)
We did not demonstrate an association between presence of the rs2230926 polymorphism in exon 3 or the 24 bp deletion in exon 1 (New 1) and TNFAIP3 mRNA level (Supplementary Figure 3) .
Transfection experiments of rs2230926 and New 3
Transient transfection assays were performed to evaluate the functional consequences of A20 mutations on the NF-kB signaling pathway. The mutated A20 variants (rs2230926G and GG insertion) were both less effective than the wild type A20 in inhibiting NF-kB-dependent transactivation of the reporter gene in response to 10 ng/ml TNFα exposure (p< 0.0001) ( Figure 3A and 3B) . Western blot analysis confirmed that the rs2930926G protein variant was expressed at a similar level as the wild type A20 protein ( Figure 3C ). As expected, no detectable InsGG variant (New 3) was observed in these conditions since the anti-A20 antibody, used for western blot, recognizes an epitope located in the C carboxy-terminal region of the protein (located in exon 7 between aa 500 and 530) that is lacking in the 122 aa Figure S4) . Second, immunocytochemistry staining with an anti-FLAG-tagged antibody was able to detect the 3 types of A20 proteins demonstrating the effectiveness of transfection ( Figure 3D ). variants of A20 may promote more active disease, which is more likely to be complicated by lymphoid malignancies. In pSS, A20 is likely to be essential for controlling NF-kB activation and ensuring that B lymphocytes avoid lymphomatous escape due to continuous stimulation as a result of the autoimmune process. Our observation that 30% of the patients with pSS and lymphoma had functional abnormalities of A20 (mutations, deletions or insertions) in the lymphomatous tissue also supports this model. By performing transfection of either wild type or mutant TNFAIP3 sequences, we confirmed that 2 of these abnormalities are hypomorphic.
The coding rs2230926G and GG insertion polymorphisms resulted in less effective inhibition of TNF-induced NF-kB activity. Our findings for rs2230926G confirm a previous study employing similar methods that also demonstrated impaired control of NF-kB activation 5 .
Although this study is unique in the examination of both germline and tumoral genetic abnormalities among pSS patients who developed lymphoma, there are a number of limitations. Most important was the lack of available lymphoma DNA from roughly a third of the tumor samples due to degradation. It is also difficult to determine whether the association of TNFAIP3 variants with pSS complicated by lymphoma relates primarily to the lymphoma or to the underlying autoimmune disease process. However, the prevalence of A20 abnormalities in pSS patients with MALT lymphoma in our study (77%) is higher than what For personal use only. on August 31, 2017. by guest www.bloodjournal.org From has been described in MALT lymphoma generally (prevalence from 22 to 28%) 6, 7 . This suggests specific involvement of A20 inactivation in lymphoma complicating autoimmune disease.
Recent studies have implicated other genes that control NF-kB activation in other types of lymphoma, such as MYD88 in Waldenstrom's macroglobulinemia 19 and Notch2 in Marginal Zone Lymphoma 20, 21 . The scenario may be somewhat different in the setting of lymphoma complicating autoimmune diseases, where genetic abnormalities could be either germline or somatic in origin. The high incidence of germline abnormalities was rather unexpected. Our results are also consistent with a "two-hit" process in which a combination of germline and somatic abnormalities of TNFAIP3 promote the development of lymphoma, as illustrated
For personal use only. on August 31, 2017. by guest www.bloodjournal.org From by one of our patients who had a germline coding abnormality (rs2230926G) and an extensive lymphoma deletion. Of interest, uncontrolled activation of NF-kB has been shown to promote the survival of germline B cells, which could lead to an increased number of somatic mutations including oncogenic mutations 4 . It will be of interest to determine whether other genes that act to control NF-kB activation contribute to the development of autoimmunity-associated lymphoma.
This study demonstrates that A20 inactivation, and thus NF-kB over-activation, plays a key 
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